Baker Bros. Advisors Lp Buys Amarin Corp PLC, Principia Biopharma Inc, Insmed Inc, Sells Erytech Pharma SA, bluebird bio Inc, Halozyme Therapeutics Inc

• New Purchases: PRNB, NVAX, VKTX, ARWR, YMAB, CRNX, AQST, CNST,
• Added Positions: AMRN, ACAD, INSM, GWPH, CMTA, BCRX, ECYT, ARGX, ANAB, SBPH,
• Reduced Positions: BLUE, ERYP, HALO, BLCM, XNCR, NTLA, SAGE, GLMD, FOMX, ARAV,
• Sold Out: EXEL, PGNX, VNDA, ACOR, SESN, GLYC, TTPH, NTRA, MGNX, AERI,

For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=BAKER+BROS.+ADVISORS+LP

1. Seattle Genetics Inc (SGEN) - 51,046,060 shares, 26.08% of the total portfolio.
2. Incyte Corp (INCY) - 34,251,309 shares, 15.68% of the total portfolio.
3. BeiGene Ltd (BGNE) - 11,959,824 shares, 13.65% of the total portfolio.
4. Alexion Pharmaceuticals Inc (ALXN) - 8,555,894 shares, 7.88% of the total portfolio.
5. Genomic Health Inc (GHDX) - 13,790,970 shares, 6.42% of the total portfolio.

Baker Bros. Advisors Lp initiated holding in Principia Biopharma Inc. The purchase prices were between $26.04 and $32.65, with an estimated average price of $28.22. The stock is now traded at around $29.43. The impact to a portfolio due to this purchase was 0.35%. The holding were 1,787,807 shares as of 2018-09-30.

Baker Bros. Advisors Lp initiated holding in Novavax Inc. The purchase prices were between $1.17 and $1.99, with an estimated average price of $1.41. The stock is now traded at around $2.48. The impact to a portfolio due to this purchase was 0.06%. The holding were 4,718,318 shares as of 2018-09-30.

Baker Bros. Advisors Lp initiated holding in Viking Therapeutics Inc. The purchase prices were between $9.7 and $19.65, with an estimated average price of $11.89. The stock is now traded at around $9.81. The impact to a portfolio due to this purchase was 0.05%. The holding were 425,000 shares as of 2018-09-30.

Baker Bros. Advisors Lp initiated holding in Arrowhead Pharmaceuticals Inc. The purchase prices were between $14 and $20.3, with an estimated average price of $16.36. The stock is now traded at around $15.19. The impact to a portfolio due to this purchase was 0.04%. The holding were 307,496 shares as of 2018-09-30.

Baker Bros. Advisors Lp initiated holding in Y-mAbs Therapeutics Inc. The purchase prices were between $24 and $26.97, with an estimated average price of $25.43. The stock is now traded at around $21.97. The impact to a portfolio due to this purchase was 0.03%. The holding were 150,000 shares as of 2018-09-30.

Baker Bros. Advisors Lp initiated holding in Crinetics Pharmaceuticals Inc. The purchase prices were between $22.66 and $36.8, with an estimated average price of $29.7. The stock is now traded at around $33.49. The impact to a portfolio due to this purchase was 0.02%. The holding were 131,250 shares as of 2018-09-30.

Baker Bros. Advisors Lp added to a holding in Amarin Corp PLC by 50.29%. The purchase prices were between $2.45 and $16.27, with an estimated average price of $3.75. The stock is now traded at around $16.78. The impact to a portfolio due to this purchase was 1.23%. The holding were 34,069,509 shares as of 2018-09-30.

Baker Bros. Advisors Lp added to a holding in Insmed Inc by 164.57%. The purchase prices were between $18.95 and $28.08, with an estimated average price of $22.61. The stock is now traded at around $15.82. The impact to a portfolio due to this purchase was 0.16%. The holding were 1,851,982 shares as of 2018-09-30.

Baker Bros. Advisors Lp added to a holding in GW Pharmaceuticals PLC by 23.28%. The purchase prices were between $129 and $174.5, with an estimated average price of $144.21. The stock is now traded at around $125.28. The impact to a portfolio due to this purchase was 0.08%. The holding were 396,700 shares as of 2018-09-30.

Baker Bros. Advisors Lp added to a holding in Clementia Pharmaceuticals Inc by 62.14%. The purchase prices were between $8.46 and $12.6, with an estimated average price of $10.53. The stock is now traded at around $11.82. The impact to a portfolio due to this purchase was 0.05%. The holding were 1,933,624 shares as of 2018-09-30.

Baker Bros. Advisors Lp added to a holding in Spring Bank Pharmaceuticals Inc by 64.32%. The purchase prices were between $11.07 and $14.41, with an estimated average price of $12.52. The stock is now traded at around $9.96. The impact to a portfolio due to this purchase was 0.02%. The holding were 613,144 shares as of 2018-09-30.

Baker Bros. Advisors Lp added to a holding in AnaptysBio Inc by 54.73%. The purchase prices were between $68.73 and $101.95, with an estimated average price of $82.97. The stock is now traded at around $71.38. The impact to a portfolio due to this purchase was 0.02%. The holding were 113,086 shares as of 2018-09-30.

Baker Bros. Advisors Lp sold out a holding in Exelixis Inc. The sale prices were between $15.87 and $22.4, with an estimated average price of $19.52.

Baker Bros. Advisors Lp sold out a holding in Progenics Pharmaceuticals Inc. The sale prices were between $5.62 and $9.18, with an estimated average price of $7.69.

Baker Bros. Advisors Lp sold out a holding in Vanda Pharmaceuticals Inc. The sale prices were between $18.25 and $23, with an estimated average price of $20.38.

Baker Bros. Advisors Lp sold out a holding in GlycoMimetics Inc. The sale prices were between $13.7 and $17.12, with an estimated average price of $15.13.

Baker Bros. Advisors Lp sold out a holding in Sesen Bio Inc. The sale prices were between $1.54 and $2.38, with an estimated average price of $1.95.

Baker Bros. Advisors Lp sold out a holding in Acorda Therapeutics Inc. The sale prices were between $17.25 and $30.55, with an estimated average price of $25.89.